|
Volumn 68, Issue 11, 2013, Pages 1483-1484
|
Reply
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CARBOPLATIN;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DRUG;
IMMUNOGLOBULIN E;
OXALIPLATIN;
PACLITAXEL;
RITUXIMAB;
ANTINEOPLASTIC AGENT;
CLINICAL IMMUNOLOGY;
CLINICAL PROTOCOL;
DESENSITIZATION;
DRUG HYPERSENSITIVITY;
DRUG SAFETY;
GOLD STANDARD;
HEALTH CARE PERSONNEL;
HIGH RISK PATIENT;
HUMAN;
LETTER;
PATIENT SAFETY;
PRIORITY JOURNAL;
PROCESS OPTIMIZATION;
SKIN TEST;
FEMALE;
IMMUNOLOGY;
MALE;
METHODOLOGY;
NOTE;
ANTINEOPLASTIC AGENTS;
DESENSITIZATION, IMMUNOLOGIC;
DRUG HYPERSENSITIVITY;
FEMALE;
HUMANS;
IMMUNOGLOBULIN E;
MALE;
|
EID: 84904053152
PISSN: 01054538
EISSN: 13989995
Source Type: Journal
DOI: 10.1111/all.12228 Document Type: Letter |
Times cited : (9)
|
References (3)
|